NASDAQ:RXDX
Prometheus Biosciences, Inc.
- Stock
Last Close
199.74
15/06 20:00
Market Cap
9.56B
Beta: −0.60
Volume Today
1.79M
Avg: 983.04K
PE Ratio
−63.62
PFCF: −88.63
Dec '14 | Dec '15 | Dec '16 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | ||
|---|---|---|---|---|---|---|---|---|
net income | -39.99M - | -92.46M 131.20% | -103.64M 12.09% | -16.73M 83.86% | -31.14M 86.14% | -90.19M 189.65% | -141.75M 57.16% | |
depreciation and amortization | 527.67K - | 2.04M 286.03% | 3.48M 70.74% | 35K 98.99% | 109K 211.43% | 258K 136.70% | 629K 143.80% | |
deferred income tax | -4.29M - | 1.91M 144.58% | 659K 65.55% | -2.68M 506.98% | ||||
stock based compensation | 2.28M - | 5.34M 134.16% | 7.72M 44.45% | 206K 97.33% | 739K 258.74% | 10.70M 1,347.63% | 20.86M 95.01% | |
change in working capital | 12.86M - | 47.65M 270.59% | -17.12M 135.92% | -334K 98.05% | -1.33M 297.31% | 12.82M 1,065.86% | -1.18M 109.18% | |
accounts receivables | -1.09M - | 7K 100.64% | 50K 614.29% | |||||
inventory | -6.43M - | -3.35M 47.96% | 2.55M 176.09% | |||||
accounts payables | 163.66K - | 2.86M 1,645.04% | 95K 96.67% | 591K 522.11% | -480K 181.22% | 103K 121.46% | -307K 398.06% | |
other working capital | 12.69M - | 44.79M 252.87% | -17.21M 138.43% | -925K 94.63% | 6.67M 820.97% | 16.05M 140.71% | -3.46M 121.58% | |
other non cash items | -8.17M - | -13.37M 63.76% | 19.45M 245.42% | 916K 95.29% | 1.69M 84.17% | 2.26M 33.85% | 865K 61.69% | |
net cash provided by operating activities | -32.49M - | -50.80M 56.37% | -90.11M 77.38% | -20.20M 77.59% | -28.02M 38.72% | -63.51M 126.66% | -123.25M 94.09% | |
investments in property plant and equipment | -3.12M - | -3.52M 12.98% | -2.45M 30.41% | -279K 88.62% | -204K 26.88% | -1.14M 456.86% | -2.70M 137.94% | |
acquisitions net | 403.78M - | |||||||
purchases of investments | -89.29M - | -148.11M 65.88% | -123.86M 16.38% | -478.68M - | ||||
sales maturities of investments | 18.06M - | 90.66M 402.05% | 140.50M 54.97% | 77.60M - | ||||
other investing activites | 15.50K - | 75K - | 8.21M 10,849.33% | -859K 110.46% | -403.78M - | |||
net cash used for investing activites | -74.33M - | -60.97M 17.97% | 14.27M 123.40% | 7.93M 44.40% | -1.06M 113.40% | -1.14M 6.87% | -403.78M 35,443.93% | |
debt repayment | -10.02M - | -172K 98.28% | -17.44M 10,038.37% | -7.96M - | ||||
common stock issued | 141.59M - | 53.89M 61.94% | 38K 99.93% | 197K 418.42% | 218.50M 110,813.71% | 589.39M 169.74% | ||
common stock repurchased | 428K - | |||||||
dividends paid | -428K - | |||||||
other financing activites | 10.02M - | -141.42M 1,510.98% | -36.45M 74.22% | 9.72M 126.66% | 79.69M 720.10% | 57.16M 28.27% | -27.19M 147.57% | |
net cash used provided by financing activities | -11.23M - | 141.42M 1,359.55% | 36.27M 74.35% | 9.76M 73.11% | 79.89M 718.92% | 267.69M 235.10% | 562.20M 110.02% | |
effect of forex changes on cash | 72.59M - | 10.39M 85.68% | 17.53M 68.67% | 123.25M - | ||||
net change in cash | -45.46M - | 40.04M 188.07% | -22.04M 155.06% | -2.51M 88.62% | 50.80M 2,124.91% | 203.05M 299.67% | 35.17M 82.68% | |
cash at beginning of period | 51.80M - | 6.35M 87.75% | 46.38M 630.90% | 10.88M 76.54% | 8.37M 23.06% | 54.20M 547.49% | 257.25M 374.63% | |
cash at end of period | 6.35M - | 46.38M 630.94% | 24.34M 47.52% | 8.37M 65.61% | 59.18M 606.92% | 257.25M 334.73% | 292.42M 13.67% | |
operating cash flow | -32.49M - | -50.80M 56.37% | -90.11M 77.38% | -20.20M 77.59% | -28.02M 38.72% | -63.51M 126.66% | -123.25M 94.09% | |
capital expenditure | -3.12M - | -3.52M 12.98% | -2.45M 30.41% | -279K 88.62% | -204K 26.88% | -1.14M 456.86% | -2.70M 137.94% | |
free cash flow | -35.61M - | -54.32M 52.57% | -92.56M 70.39% | -20.48M 77.88% | -28.22M 37.83% | -64.64M 129.04% | -125.96M 94.86% |
All numbers in USD (except ratios and percentages)